How Treatment Changes With the Stage of Head and Neck Cancer
A stage-based map of curative treatment: single-modality therapy for early disease, combined modality therapy for locally advanced disease, and systemic therapy for recurrence or metastasis.
Early-stage (I–II) head and neck cancer is usually treated with one modality — surgery or radiotherapy — with roughly 70–90% five-year survival in guideline summaries. Locally advanced (III–IVB) disease requires combined treatment such as surgery plus postoperative radiotherapy/chemoradiotherapy or definitive cisplatin-based chemoradiotherapy. Recurrent or metastatic disease is managed with systemic therapy, immunotherapy, local salvage treatment or palliation.
What is the standard treatment for early-stage disease?
One treatment, chosen to maximise cure and function.
For stage I–II disease, either surgery or definitive radiotherapy can be curative, and guideline summaries quote similar 70–90% five-year survival. The choice is driven by the subsite and the functional cost: a T1 glottic cancer may be treated with laser excision or radiotherapy to preserve voice; a small oral cavity cancer is usually excised with clear margins and neck management; stage I nasopharyngeal carcinoma is treated with radiotherapy alone because surgery is not anatomically practical.
What changes for locally advanced disease?
Combined modality treatment is the standard, planned by a tumour board.
- Resectable disease: radical surgery with neck dissection and reconstruction, followed by risk-adapted postoperative radiotherapy (commonly 60–66 Gy in 2 Gy fractions) or concurrent chemoradiotherapy for positive margins or extranodal extension.
- Unresectable or organ-preservation candidates: definitive concurrent chemoradiotherapy, conventionally with cisplatin 100 mg/m² every three weeks in guideline-based protocols.
- Larynx/hypopharynx preservation: induction chemotherapy (TPF) followed by response-adapted radiotherapy or chemoradiotherapy in selected patients.
- Nasopharyngeal carcinoma: induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy for stage III–IVA disease in current Chinese and international practice.
- IMRT is the recommended radiotherapy technique to reduce long-term toxicity to salivary glands, mandible, swallowing structures and the central nervous system.
What about recurrent or metastatic disease?
Local or regional recurrence may still be curable with salvage surgery, re-irradiation or, for nasopharyngeal carcinoma, endoscopic/skull-base resection. Distant metastasis is generally treated with systemic therapy: PD-1 inhibitors (pembrolizumab alone or with chemotherapy for PD-L1-expressing disease; nivolumab or pembrolizumab after platinum failure), cetuximab-containing regimens, targeted agents for specific mutations, or best supportive care depending on performance status and goals.
Treatment de-escalation for HPV-positive disease — lower radiotherapy dose or replacing cisplatin with cetuximab — has produced inferior outcomes in randomised trials and should be done only inside a clinical trial.
Why does treatment timing matter?
Delays in starting treatment worsen outcomes in head and neck oncology. NCCN-derived summaries advise that surgery for advanced disease should not be delayed beyond about four weeks from diagnosis, and postoperative radiotherapy should start as soon as healing allows — ideally within six weeks when high-risk features are present. This is one reason patients consider centres with short waiting times, but it must never come at the cost of an incomplete work-up.
Frequently asked questions
Is surgery always better than radiotherapy for early cancer?
No. For many early glottic and oropharyngeal tumours, surgery and radiotherapy offer comparable cancer control. The decision is about functional outcome, the need for general anaesthesia, access to a six-to-seven-week radiotherapy course, and the long-term effects of radiation.
Why is chemotherapy added to radiotherapy?
Cisplatin acts as a radiosensitiser and treats microscopic systemic disease. Concurrent chemoradiotherapy improves locoregional control and survival in locally advanced disease, at the cost of more acute toxicity — blood count suppression, nausea, kidney and hearing effects, and worse mucositis.
What is adjuvant treatment?
Treatment given after surgery to reduce recurrence risk. Indications include positive or close margins, extranodal extension, multiple positive nodes, pT3/T4 disease, perineural or lymphovascular invasion. Radiotherapy alone is used for intermediate risk; concurrent chemoradiotherapy for positive margins or extranodal extension.
Can treatment be paused or split between two countries?
Radiotherapy and concurrent chemotherapy should not be interrupted or split between centres without a formal transfer plan: dose, fractionation and cumulative drug records must be reconciled. Surgery followed by adjuvant radiotherapy in another country is possible if you carry a complete operative, pathology and imaging record and the new team formally re-plans the case.
Sources for this guide
Applying this to your own case?
Start with a remote review of your records, then compare the written plan with the options you have at home.
Records checklist How to compare plansMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.